United-Guardian Q1 Sales +15.7% to $2.87M; Net Income +46%; EPS $0.18
United-Guardian, Inc. reported strong financial results for the first quarter of 2026, with sales increasing by 15.7% to $2.87 million and net income rising by 46% to $818,902, or $0.18 per share. This growth was primarily driven by a 24% increase in pharmaceutical sales, particularly for Renacidin , and a 21% rise in cosmetic ingredient sales, boosted by a 45% increase in purchases from its largest distributor, Ashland Specialty Ingredients, which had previously carried excess inventory. The company's income was also supplemented by $303,133 in settlement income. United-Guardian is optimistic about continued sales growth in 2026 due to resumed regular purchasing patterns, new distribution agreements, and expanded product lines.
Key Highlights
- Q1 2026 net sales increased 15.7% to $2,872,222 from $2,481,127 in Q1 2025.
- Q1 2026 net income rose 46.0% to $818,902 from $560,895 in Q1 2025.
- Earnings per share for Q1 2026 increased to $0.18 from $0.12 in Q1 2025.
- Pharmaceutical sales grew by 24% in Q1 2026, driven by Renacidin demand.
- Cosmetic ingredient sales increased by 21%, with distributor purchases up 45%.
- Recognized $303,133 in settlement income from a contract manufacturer.